| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Thoracic and Cardiovascular Surgery [A. P., J. A. R., S. G. S.], and Surgical Oncology [K. K. H., S. A. V.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Introgen Therapeutics Inc, Houston, Texas 77030 [S. C., A. M. M., H. Z-Y., A. L. S.]; and Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida 33136 [G. N. B., S. B]
| ABSTRACT |
|---|
|
|
|---|
subunit of eukaryotic translation initiation factor 2 (eIF-2
) and the induction of apoptosis in lung cancer cells. Treatment with 2-aminopurine (2-AP), a serine/threonine kinase inhibitor, inhibits PKR activation, eIF2
phosphorylation, and apoptosis induction by Ad-mda7. Additionally, PKR null but not wild-type fibroblasts are resistant to Ad-mda7-induced apoptosis. These results suggest that the activation of PKR and its downstream targets may be a critical pathway for Ad-mda7-mediated apoptosis. | Introduction |
|---|
|
|
|---|
, which can lead to the inhibition of protein synthesis, growth suppression, and apoptosis induction (10, 11, 12)
. We report in this study that transduction of lung cancer cells with Ad-mda7 results in PKR activation, eIF-2
phosphorylation, and apoptosis induction. Pretreatment of the cells with 2-AP (a serine/threonine kinase inhibitor) inhibits PKR activation, eIF-2
phosphorylation, and apoptosis. Additionally, PKR null but not wild-type fibroblasts are resistant to Ad-mda7-induced apoptosis. These results suggest a novel role for PKR as a critical mediator of Ad-mda7 apoptosis induction in lung cancer cells. | Materials and Methods |
|---|
|
|
|---|
Adenovirus Production.
Construction of the Ad-mda7, AdBak, and Ad-Luc vectors have been previously reported (3
, 14)
. The transduction efficiencies of adenoviral vectors in various cancer cell lines were determined by infecting cells with Ad-LacZ and then determining the titers needed to transduce at least 70% of the cells.
Flow Cytometry Analysis and XTT assay.
We measured apoptotic cells by propidium iodide staining and FACS analysis. Cells were harvested, pelleted by centrifugation, and resuspended in PBS containing 50 µg/ml propidium iodide, 0.1% Triton X-100, and 0.1% sodium citrate. Samples were stored at 4°C for 16 h and vortexed before FACS analysis (Becton-Dickenson FACScan, Mountain View, CA; FL-3 channel). Cellular viability was assessed with the XTT assay by growing cells in 96-well plates at 100-µL volume/well. After treatment with Ad-mda7 or control vectors, cells were incubated with the tetrazolium salt XTT according to the Roche protocol (Roche Diagnostics, Mannheim, Germany). Viability was assessed spectrophotometrically on an ELISA plate reader.
Immunoblot Assays.
Forty-eight h after transfection, cell extracts were prepared for immunoblot assays as described previously (14)
. The following antibodies were used: for PKR (K-17); eIF-2
, ß-actin, and p38 (A-12); phosphospecific p38 (D-8); stat1 (C-136); phosphospecific stat1 (A-2); stat3 (F-2); phosphospecific stat3 (B-7); anti-Tyk2 (C-20) and phosphospecific anti-Tyk (PY-99; Santa Cruz Biotechnology, Santa Cruz, CA); caspase 3, caspase-9, caspase-8, and Bid (PharMingen, San Diego, CA), and the phosphospecific PKR (pT451) and eIF-2
(pS51; BioSource International, Camarillo, CA). The polyclonal and monoclonal antibodies to Mda-7 were obtained from Introgen Therapeutics, Inc. (Houston, TX).
Measurement of Cellular Protein Synthesis.
Cells were treated with Ad-mda7 or Ad-Luc for 48 h. Where indicated in the experiment, cells were treated with 1 mM 2-AP for 48 h. Measurement of protein synthesis was performed as described previously (15)
. After treatment,
1 x 106 cell equivalents were incubated with L-[U-14C] amino acid mixture (Amersham, Piscataway, NJ) at 2 µCi/ml for 10 min at 37°C. The reaction was terminated by the addition of 20% (wt/vol) trichloroacetic acid, and the radioactivity in the acid-precipitable fraction was measured in a scintillation counter.
Statistical Analysis.
The data reported in Figs. 1
, 3
, and 4
represent the mean of three or more independent experiments and the bars show the SD. ANOVA and two-tailed Students t test were used for statistical analysis of multiple groups and pair-wise comparison, respectively, with P < 0.05 considered significant.
|
|
|
| Results |
|---|
|
|
|---|
Ad-mda7 Activates PKR, eIF2
, and Other PKR Substrate Targets.
To determine whether Ad-mda7 could activate PKR in vitro, Ad-mda7-treated cells (A549) were assessed by immunoblot assay for the presence of phosphorylated PKR. Only Ad-mda7-treated cells demonstrated increased expression of PKR and its active phosphorylated form (Fig. 2A)
. Activation of the serine/threonine kinase was also demonstrated by phosphorylation of PKRs downstream targets eIF-2
, Tyk2, Stat1, Stat3, and p38 (Fig. 2, A and B)
. Treatment with Ad-mda7 led to subsequent apoptosis induction with caspase 3, 8, and 9 activation, and Bid and PARP cleavage (Fig. 2C)
. The activation of PKR appeared to be specific for Ad-mda7 and upstream of caspase activation because pretreatment with caspase inhibitors failed to block PKR phosphorylation (data not shown).
|
phosphorylation (Fig. 3B)
phosphorylation was manifested by normal protein synthesis and apoptotic induction (Fig. 3, A and C)| Discussion |
|---|
|
|
|---|
(4)
. These studies, however, have been largely correlative and have not addressed which, if any, upstream genes Ad-mda7 engages before caspase activation and apoptosis.
In this paper, we demonstrate for the first time clear up-regulation of the IFN-induced, serine/threonine protein kinase PKR. Ad-mda7 transduction of lung cancer cells leads to PKR induction in a p53-independent manner (Fig. 1, A and B)
. We have also seen PKR up-regulation in other types of cancer cells, including colorectal and breast, which suggests that this relationship is not specific to lung cancer cells (data not shown). Up-regulation of PKR also appears specific for Ad-mda7 because little PKR change is seen after transduction of cancer cells with adenoviral vectors containing the luciferase reporter gene or other pro-apoptotic genes such as Ad-Bak (Fig. 1, B and C)
. In addition, PKR induction does not appear to be attributable to nonspecific caspase cleavage because blockage with caspase inhibitors did not abrogate PKR up-regulation, and Ad-Bak apoptosis induction failed to induce PKR (Fig. 1C)
.
PKR is well characterized in the literature as an antiviral immune mediator responding to viral dsRNA by activation of eIF-2
, protein synthesis inhibition, and blockage of viral protein production. Many viruses contain inhibitory proteins to block PKR activity (7)
. Our studies suggest that Ad-mda7-induced PKR up-regulation is not solely a response to the adenoviral construct, because Ad-Luc and Ad-Bak fail to induce PKR activation and Ad-Bak is not dependent on PKR genomic status to induce apoptosis in MEFs. Indeed, our studies give further support to the premise that one of PKRs main cellular functions is as a regulator of tumorigenesis (7)
. Activation of PKR in HeLa, Cos1, U937, and NIH3T3 tumor cells leads to apoptosis induction and cellular death (7)
. Additionally, MEFs from PKR knockout mice are resistant to apoptotic cell death in response to a variety of stimuli including dsRNA, tumor necrosis factor
, and lipopolysaccharide (12)
. Further evidence of PKRs antitumorigenic function includes critical tumorigenic deletions in myelodysplasias of the IRF-1 gene that appear to be associated with decreased PKR levels (7
, 17)
and in associations with PKR expression and prolonged lung and colorectal cancer survival (18)
.
PKR appears to mediate antitumorigenic activity through the activation of multiple transduction pathways culminating in growth inhibition and apoptosis induction. Activation of these pathways occurs after the latent, inactive homodimeric form, located predominantly in the cytoplasm, is induced by activating signals to undergo conformational changes leading to auto-phosphorylation and activation (9)
. Once activated, PKR is able to phosphorylate various substrate targets that are important in growth control and apoptosis induction (10
, 11)
. Our immunoprecipitation studies are consistent with this model showing PKR activation after Ad-mda7 transduction leading to increases in phosphorylated (active) PKR and phosphorylated eIF-2
(Fig. 2A)
. We, also, demonstrate after Ad-mda7 transduction, the phosphorylation of several other PKR substrate targets that may be associated with apoptosis induction and growth control, including Stat1, Stat3, and p38 (19
, 20)
. The activation of PKR appears to be a critical event in Ad-mda7 apoptosis (as opposed to Ad-Bak) because the inhibition of PKR with the specific threonine/kinase inhibitor, 2-AP leads to the inhibition of Ad-mda7 apoptosis, eIF-2
phosphorylation, and protein synthesis inhibition. The inhibition of protein synthesis may be critical to the induction of apoptosis possibly because of the regulation of one or more short-lived proteins involved in apoptosis inhibition. Alternatively, other pathways controlled by PKR may be important, such as those involved in the regulation of NF-
B, p53, MEK, IRF-1, or FADD (7
, 21, 22, 23)
.
Although multiple pathways may be involved, PKR activation appears to be critical for Ad-mda7 apoptosis because MEFs lacking PKR were unable to undergo apoptosis as opposed to MEFs with wild-type PKR. This inhibition of apoptosis appeared specific to MDA-7 because transduction of MEFs lacking PKR with the pro-apoptotic Ad-Bak vector led to unimpaired apoptosis. These observations can be explained by a model in which MDA-7 and PKR are upstream of the caspases and the pro-apoptotic Bak gene. In this model, mda-7 induces PKR up-regulation with subsequent activation of various cellular pathways that lead to caspase activation and apoptosis induction. Bak being downstream of PKR and MDA-7 is not dependent on PKR activation to induce apoptosis or caspase cleavage. It is, also, interesting to note that we saw clear evidence of Bid and caspase 8 cleavage, which is consistent with other laboratories that have suggested PKR apoptosis is often mediated through activation of the Fas/FADD death receptor pathway with caspase-8 and Bid cleavage leading to subsequent caspase 3 and 9 activation (23) .
In summary, our paper demonstrates for the first time that Ad-mda7 leads to the rapid induction of PKR with subsequent phosphorylation of eIF-2
, other PKR target substrates, and apoptosis induction. Specific inhibition of PKR by 2-AP in lung cancer cells inhibits Ad-mda7-induced PKR activation, PKR substrate target phosphorylation, and apoptosis induction. As evidenced by PKR null fibroblasts, Ad-mda7 apoptosis appears dependent on a functional PKR pathway. These results suggest a novel role for the multifunctional PKR gene as a critical mediator of Ad-mda7 apoptosis and give insight into the mechanism of action of Ad-mda7. In the future, novel therapeutic strategies aimed at activating PKR or blocking PKR inhibitors may be able to further enhance the antitumoral efficacy of Ad-mda7.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported in part by Grants P01 CA78778-01A1 from the National Cancer Institute and the NIH (to J. A. R., S. G. S.);by SBIR Grant S/C 1R43 CA86587-1 (to SGS, SC); by SPORE Grant 2P50-CA70970-04); by gifts to the Division of Surgery, from Tenneco and Exxon for the Core Laboratory Facility; by the University of Texas M. D. Anderson Cancer Center Support Core Grant (CA 16672); by donations from the Charles Rogers Memorial and Gene Therapy Donor funds; by a grant from the Tobacco Settlement Funds as appropriated by the Texas State Legislature (Project 8); by a grant from the W. M. Keck Foundation,; and a sponsored research agreement with Introgen Therapeutics, Inc. (SR93-004-1). ![]()
2 These laboratories contributed equally to this work. ![]()
3 To whom requests for reprints should be addressed, at Department of Thoracic and Cardiovascular Surgery at the University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, Texas 77030. Phone: (713) 745-4530; Fax: (713) 794-4901, E-mail: sswisher{at}mdanderson.org ![]()
4 The abbreviations used are: mda-7, melanoma differentiation-associated-7 (gene); 2-AP, 2-aminopurine; dsRNA, double-stranded RNA; MEF, mouse embryo fibroblast; eIF-2
,
subunit of eukaryotic translation initiation factor 2; ds, double-stranded; PKR, dsRNA-dependent protein kinase; IL, interleukin; Ad-mda7, adenoviral-mediated overexpression of mda-7; FACS, fluorescence-activated cell sorting; XTT, 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt; PARP, poly(ADPribose) polymerase. ![]()
Received 1/28/02. Accepted .
| REFERENCES |
|---|
|
|
|---|
phosphorylation. J. Biol. Chem., 276: 41620-41628, 2001.
(eIF2
) promotes complex formation between eIF2
(P) and causes inhibition in the guanine nucleotide exchange activity of eIF2B. Biochemistry, 39: 12929-12938, 2000.[Medline]
B by IFN-
in a STAT1-independent pathway. J. Immunol., 166: 6170-6180, 2001.
subunit of eukaryotic translation initiation factor 2 and NF-
B. Mol. Cell. Biol., 19: 4653-4663,
This article has been cited by other articles:
![]() |
G. Clerzius, J.-F. Gelinas, A. Daher, M. Bonnet, E. F. Meurs, and A. Gatignol ADAR1 Interacts with PKR during Human Immunodeficiency Virus Infection of Lymphocytes and Contributes to Viral Replication J. Virol., October 1, 2009; 83(19): 10119 - 10128. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hu, W. Hofstetter, X. Wei, W. Guo, Y. Zhou, A. Pataer, H. Li, B. Fang, and S. G. Swisher Double-Stranded RNA-Dependent Protein Kinase-Dependent Apoptosis Induction by a Novel Small Compound J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 866 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pataer, W. Hu, L. Xiaolin, S. Chada, J. A. Roth, K. K. Hunt, and S. G. Swisher Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing Mol. Cancer Ther., August 1, 2008; 7(8): 2528 - 2535. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Armstrong, M. Gantier, L. Li, W. Y. Chung, A. McCann, J. A. Baugh, and S. C. Donnelly Small Interfering RNAs Induce Macrophage Migration Inhibitory Factor Production and Proliferation in Breast Cancer Cells via a Double-Stranded RNA-Dependent Protein Kinase-Dependent Mechanism J. Immunol., June 1, 2008; 180(11): 7125 - 7133. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Zykova, F. Zhu, Y. Zhang, A. M. Bode, and Z. Dong Involvement of ERKs, RSK2 and PKR in UVA-induced signal transduction toward phosphorylation of eIF2{alpha} (Ser51) Carcinogenesis, July 1, 2007; 28(7): 1543 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sauane, P. Gupta, I. V. Lebedeva, Z.-z. Su, D. Sarkar, A. Randolph, K. Valerie, R. V. Gopalkrishnan, and P. B. Fisher N-Glycosylation of MDA-7/IL-24 Is Dispensable for Tumor Cell-Specific Apoptosis and "Bystander" Antitumor Activity Cancer Res., December 15, 2006; 66(24): 11869 - 11877. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Garcia, J. Gil, I. Ventoso, S. Guerra, E. Domingo, C. Rivas, and M. Esteban Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action Microbiol. Mol. Biol. Rev., December 1, 2006; 70(4): 1032 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Fisher Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Res., November 15, 2005; 65(22): 10128 - 10138. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Oida, B. Gopalan, R. Miyahara, S. Inoue, C. D. Branch, A. M. Mhashilkar, E. Lin, B. N. Bekele, J. A. Roth, S. Chada, et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer Mol. Cancer Ther., February 1, 2005; 4(2): 291 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aggarwal, Y. Takada, A. M. Mhashilkar, K. Sieger, S. Chada, and B. B. Aggarwal Melanoma Differentiation-Associated Gene-7/IL-24 Gene Enhances NF-{kappa}B Activation and Suppresses Apoptosis Induced by TNF J. Immunol., October 1, 2004; 173(7): 4368 - 4376. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kazemi, S. Papadopoulou, S. Li, Q. Su, S. Wang, A. Yoshimura, G. Matlashewski, T. E. Dever, and A. E. Koromilas Control of {alpha} Subunit of Eukaryotic Translation Initiation Factor 2 (eIF2{alpha}) Phosphorylation by the Human Papillomavirus Type 18 E6 Oncoprotein: Implications for eIF2{alpha}-Dependent Gene Expression and Cell Death Mol. Cell. Biol., April 15, 2004; 24(8): 3415 - 3429. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ramesh, A. M. Mhashilkar, F. Tanaka, Y. Saito, C. D. Branch, K. Sieger, J. B. Mumm, A. L. Stewart, A. Boquio, L. Dumoutier, et al. Melanoma Differentiation-associated Gene 7/Interleukin (IL)-24 Is a Novel Ligand That Regulates Angiogenesis via the IL-22 Receptor Cancer Res., August 15, 2003; 63(16): 5105 - 5113. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pataer, S. Chada, K. K. Hunt, J. A. Roth, and S. G. Swisher Adenoviral melanoma differentiation-associated gene 7 induces apoptosis in lung cancer cells through mitochondrial permeability transition-independent cytochrome c release J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1328 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ekmekcioglu, J. A. Ellerhorst, J. B. Mumm, M. Zheng, L. Broemeling, V. G. Prieto, A. L. Stewart, A. M. Mhashilkar, S. Chada, and E. A. Grimm Negative Association of Melanoma Differentiation-associated Gene (mda-7) and Inducible Nitric Oxide Synthase (iNOS) in Human Melanoma: MDA-7 Regulates iNOS Expression in Melanoma Cells Mol. Cancer Ther., January 1, 2003; 2(1): 9 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Parrish-Novak, W. Xu, T. Brender, L. Yao, C. Jones, J. West, C. Brandt, L. Jelinek, K. Madden, P. A. McKernan, et al. Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes. DIFFERENCES IN RECEPTOR-LIGAND INTERACTIONS MEDIATE UNIQUE BIOLOGICAL FUNCTIONS J. Biol. Chem., November 27, 2002; 277(49): 47517 - 47523. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Meric and K. K. Hunt Translation Initiation in Cancer: A Novel Target for Therapy Mol. Cancer Ther., September 1, 2002; 1(11): 971 - 979. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |